Studies reveal how shingles vaccine should be used in arthritis patients

August 28, 2017, Wiley

New research indicates that the live varicella-zoster vaccine—which is given to protect against shingles—elicits robust immune responses in patients when administered several weeks prior to the start of treatment with the arthritis drug tofacitinib. The Arthritis & Rheumatology findings are encouraging because patients with rheumatoid arthritis have a higher risk of developing shingles than other adults, and tofacitinib and certain other disease-modifying antirheumatic drugs are thought to further increase this risk. Importantly, however, the virus should not be given to patients who have not had the chicken pox in the past.

Kevin Winthrop MD, MPH of the Oregon Health and Science University and his colleagues conducted the research, which consisted of two studies. In one study, 112 patients with active rheumatoid were vaccinated and then randomized to receive either tofacitinib (a Janus kinase inhibitor) or placebo, initiated 2-3 weeks post-vaccination.

Patients developed robust immune responses to the , and the start of tofacitinib after vaccination had no negative impact on the established immune response. In fact, patients treated with tofacitinib had similar or even higher immune responses to the vaccine compared with placebo-treated patients, perhaps because they had better control of their rheumatoid arthritis.

"We showed that the vaccine was adequately immunogenic in patients whether they were starting tofacitinib or placebo in a few weeks, and the immunogenicity and the response to the vaccine were similar to what we've seen outside the rheumatoid arthritis setting in general population studies," said Dr. Winthrop.

One patient experienced disseminated varicella infection after starting tofacitinib. The investigators discovered that this patient was the sole participant who did not have in the past. The finding emphasizes the importance of only giving the vaccine to patients who have had chicken pox because shingles arises when the that remains dormant in the body is reactivated. Arthritis drugs that suppress the immune system put patients at an elevated risk of disseminated varicella infection following vaccination.

The second study by the group looked to see if concomitant use of what are called conventional synthetic disease-modifying antirheumatic drugs (csDMARDs, such as methotrexate and chloroquine) or corticosteroids contribute to the increased risk of shingles linked to tofacitinib. The study involved an analysis of 19 clinical trials involving a total of 6192 patients with rheumatoid arthritis.

Shingles rates were lowest for patients taking tofacitinib without csDMARDs or corticosteroids and highest for those taking tofacitinib with csDMARDs and corticosteroids. The investigators noted that similar efficacy has been observed with tofacitinib in phase III clinical studies regardless of whether it is administered as monotherapy or in combination with csDMARDs and/or corticosteroids. Therefore, the use of tofacitinib alone for the treatment of rheumatoid arthritis should be considered to help reduce the risk of shingles in vaccinated patients, provided that the patient's arthritis remains controlled on the drug.

"If you want to lower shingles risk for patients, there are two strategies: one is vaccinating them and the other is getting them off steroids and methotrexate if you can," said Dr. Winthrop.

Explore further: New oral treatment option for rheumatoid arthritis

More information: "The Safety and Immunogenicity of Live Zoster Vaccination in Rheumatoid Arthritis Patients Before Starting Tofacitinib: A Randomized Phase II Trial." Arthritis & Rheumatology (2017). DOI: 10.1002/art.40187

Related Stories

New oral treatment option for rheumatoid arthritis

June 19, 2017
Patients suffering from rheumatoid arthritis are treated for around six months with the standard anti-rheumatic agent methotrexate, to which many patients respond very well. However, if they do not respond and no remission ...

Tofacitinib ups rheumatoid arthritis treatment response

August 22, 2013
(HealthDay)—The addition of tofacitinib to rheumatoid arthritis (RA) treatment regimens improves patient response to non-biologic disease-modifying antirheumatic drugs (DMARDs), according to a study published in the Aug. ...

New effective treatments for psoriatic arthritis patients

June 16, 2017
The results of two studies presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference revealed promising data supporting two new drug classes for the treatment of psoriatic arthritis (PsA).

Study shows efficacy of new rheumatoid arthritis drug

August 9, 2012
(Medical Xpress) -- A new study involving researchers from Karolinska Institutet demonstrates the efficacy of Tofacitinib, a new drug for rheumatoid arthritis. According to the study, which is published in The New England ...

Newly approved oral medication slows rheumatoid arthritis joint damage

January 24, 2013
A Phase 3 clinical trial demonstrates that tofacitinib improves disease activity and inhibits progression of joint damage in rheumatoid arthritis (RA) patients who did not respond to methotrexate (MTX). Results of the 12-month ...

Recommended for you

Scientists use nanotechnology to detect molecular biomarker for osteoarthritis

March 12, 2018
For the first time, scientists at Wake Forest Baptist Medical Center have been able to measure a specific molecule indicative of osteoarthritis and a number of other inflammatory diseases using a newly developed technology.

Biological engineers discover why a promising drug failed in clinical trials

March 7, 2018
Pharmaceutical companies once considered a protein called p38 a very attractive target for treating rheumatoid arthritis. Arthritis patients usually have elevated activity of this inflammation-producing protein, and in lab ...

Scorpion venom component can reduce severity of rheumatoid arthritis

February 26, 2018
A treatment that improves the lives of nearly 1.3 million people with rheumatoid arthritis might one day originate from scorpion venom. A group of researchers led by Dr. Christine Beeton at Baylor College of Medicine has ...

New device for low-cost single-cell analysis identifies fibroblast subtypes in rheumatoid arthritis patients

February 23, 2018
Single-cell analysis holds enormous potential to study how individual cells influence disease and respond to treatment, but the lack of cost-effective and user-friendly instrumentation remains challenging. As described in ...

Scientists find key proteins control risk of osteoarthritis during aging

February 14, 2018
More than 30 million Americans suffer from osteoarthritis making it one of the most common age-related diseases.

Acute treatment suppresses posttraumatic arthritis in ankle injury

February 7, 2018
A University of Iowa study has identified a method for inhibiting the occurrence of an aggressive form of arthritis that frequently develops following a severe traumatic injury. The preclinical work demonstrates the potential ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.